Results 131 to 140 of about 7,817 (197)

Assessment of interleukin-10 promoter variant (-1082A/G) and cytokine production in patients with hemolytic uremic syndrome. [PDF]

Front Pediatr, 2023
Mongelos MA, Sosa FN, Pineda GE, Fiorentino G, Santiago A, Abelleyro MM, Rossetti LC, Exeni R, De Brasi CD, Palermo MS, Ramos MV.   +10 more
europepmc   +1 more source

Assessment of Static Balance with and Without Cognitive Dual Task in Children with Haemophilia: A Cross-Sectional Study. [PDF]

J Funct Morphol Kinesiol
Chimeno-Hernández A, Alberola-Zorrilla P, Martín Campos J, Carrasco JJ, Pérez-Alenda S, Sánchez Zuriaga D, Aguilar-Rodríguez M.   +6 more
europepmc   +1 more source

Long-Term Follow-Up of a Portuguese Single-Centre Cohort of Persons with Haemophilia and Hepatitis C Virus Infection. [PDF]

GE Port J Gastroenterol, 2021
Pereira Guedes T, Garrido M, Kuttner Magalhães R, Moreira T, Rocha M, Maia L, Manuel Ferreira J, Morais S, Pedroto I.   +8 more
europepmc   +1 more source

Hemorragias do Sistema Nervoso Central em Hemofilia [PDF]

, 2000
Carvalho, F, Diniz, MJ, Dominguez, C, Leão, C, Vieira, A   +4 more
core  

[Current situation of rare diseases in Bogotá: Notification to Sivigila from 2019 to 2022]. [PDF]

Rev Salud Publica (Bogota), 2023
Serrano-Giraldo J, Becerra-Muñoz MP, Tijaro-Santos JA, Zarante I.   +3 more
europepmc   +1 more source

Surgical Excision of a Hemophilic Pseudotumor Causing Vascular Impingement in a Patient with Severe Hemophilia A: A Case Report. [PDF]

Rev Bras Ortop (Sao Paulo)
Pradilla JM, Tinoco A, Cely LM, Buitrago MP.   +3 more
europepmc   +1 more source

The impact of improving haemophilia A management within the Spanish National Healthcare System: a social return on investment analysis. [PDF]

BMC Health Serv Res, 2022
Soto I, Mateo J, García-Diego DA, Gil B, Ruiz-Beato E, Ivanova Y, Martín Lorenzo T, Maravilla-Herrera P, Hidalgo-Vega Á, Merino M.   +9 more
europepmc   +1 more source

Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study. [PDF]

Eur J Haematol
Ozelo MC, Luciani M, Glosli H, Kavakli K, Samji N, Makris GC, Tueckmantel C, Maas Enriquez M, Oliveira LC, Gupta S, Arbesú MG, Davoli M, Chan AKC, Mancuso ME.   +13 more
europepmc   +1 more source

Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease. [PDF]

TH Open, 2021
Sholzberg M, Khair K, Yaish H, Rodgers G, Cruz MS, Mejía CM, Čermáková Z, Matino D, Teitel J, Barrie A, Werner S, Prondzinski MVD.   +11 more
europepmc   +1 more source